system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Animals, Basic Helix-Loop-Helix Transcription Factors, Blood Flow Velocity, Cells, Cultured, Disease Models, Animal, Eukaryotic Initiation Factor-3, Fibroblast Growth Factor 2, Hindlimb, Human Umbilical Vein Endothelial Cells, Humans, Ischemia, Male, Mice, Inbred BALB C, Muscle, Skeletal, Myoblasts, Skeletal, Neovascularization, Physiologic, Protein Stability, Proto-Oncogene Proteins c-sis, RNA Interference, RNAi Therapeutics, Recovery of Function, Regional Blood Flow, Time Factors, Transfection.
user
Does silencing of eIF3e promote blood perfusion recovery after limb ischemia through stabilization of hypoxia-inducible factor 2α activity? Context: We previously observed that silencing of eukaryotic translation initiation factor 3 subunit e (eIF3e), a hypoxia-independent downregulator of hypoxia-inducible factor 2α (HIF-2α), led to neoangiogenesis by promoting HIF-2α activity under normoxic conditions. In the current study, we investigated whether temporary silencing of eIF3e in muscles affects blood flow recovery in a mouse ischemic limb model. eIF3e silencing was performed using small interfering RNA (siRNA), and changes in gene transcription and protein expression were analyzed in vitro using murine primary skeletal muscle myoblast and human primary skeletal muscle myoblast cell cultures. In unilateral femoral artery ligation experiments, eIF3e siRNA-expressing plasmids were injected into the muscles of BALB/c mice near the ligation sites, and tissue damage and loss of limb function were scored for 28 days while serial measurements of limb perfusions were performed with laser Doppler perfusion imaging. Silencing of eIF3e in murine primary skeletal muscle myoblasts led to stabilization of HIF-2α and upregulation of angiogenic transcripts, including basic fibroblast growth factor and platelet-derived growth factor B (P < .05), and the supernatant of eIF3e-silenced human primary skeletal muscle myoblasts triggered the tube formation of human umbilical vein endothelial cells. The in vivo mouse model of hindlimb ischemia revealed that single intramuscular injections of eIF3e siRNA-expressing plasmids significantly enhanced perfusion of ischemia-damaged limbs (P < .05) at days 7 and 14 and functional recovery at days 7, 14, and 21 (P < .05).
assistant
eIF3e is an angiogenesis suppressor and may be a therapeutic target for promoting angiogenesis after ischemic injuries. Final Decision: yes